Download Files:

Sovesudil (hydrochloride)

$500$4,700

Products Details

Product Description

– Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia[1][2].

Web ID

– HY-109191A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C23H23ClFN3O3

References

– [1]Ha A, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study [published online ahead of print, 2021 Jul 28]. Acta Ophthalmol. 2021;10.1111/aos.14949.|[2]Van de Velde S, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55(2):1006-1016. Published 2014 Feb 18.

Molecular Weight

– 443.90

Compound Purity

– 99.79

SMILES

– O=C(C1=CC(C2=CC(C(NC3=C(F)C=NC=C3)=O)=CC=C2CN)=CC=C1)OCCC.[H]Cl

Clinical Information

– Phase 3

Research Area

– Neurological Disease

Solubility

– DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– ROCK

Isoform

– ROCK1;ROCK2

Pathway

– Cell Cycle/DNA Damage;Cytoskeleton;Stem Cell/Wnt;TGF-beta/Smad

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.